Neumora is developing precision medicines for brain diseases by targeting novel mechanisms of action through a pipeline of clinical and preclinical programs focused on neuropsychiatric and neurodegenerative disorders. This approach addresses the significant unmet medical need for effective treatments, moving beyond traditional drug classes to improve patient outcomes and quality of life.
Funding
$737M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AD+8Founders
Product
Problem
Current treatments for many brain disorders rely on a limited number of drug classes, leaving a significant unmet need for patients due to a lack of diverse treatment options and mechanisms of action. Traditional approaches often fail to address the underlying causes of these complex diseases, resulting in suboptimal outcomes and a persistent burden on individuals and healthcare systems.
Solution
Neumora is developing precision medicines for brain diseases by targeting novel mechanisms of action. The company's pipeline consists of clinical and preclinical programs focused on neuropsychiatric and neurodegenerative disorders. Neumora employs a Precision Toolbox, integrating translational, clinical, and computational tools to generate insights that enable precision medicine approaches. This strategy aims to move beyond traditional drug classes and improve patient outcomes by addressing therapeutically relevant targets implicated in Central Nervous System (CNS) diseases with best-in-class pharmacology.
Target Audience
The primary target audience includes individuals suffering from brain diseases, as well as healthcare providers and researchers seeking more effective and targeted treatments for neuropsychiatric and neurodegenerative disorders.
Features
- Pipeline of programs targeting novel mechanisms of action in CNS diseases
- Focus on neuropsychiatric and neurodegenerative disorders
- Precision Toolbox integrating translational, clinical, and computational tools
- Development of best-in-class pharmacology for therapeutically relevant targets